Hematopoietic stem cell conditioning targets (HSC conditioning targets)

Hematopoietic stem cell (HSC) conditioning targets represent a diverse group of molecular structures on the surface of hematopoietic stem cells and immune cells that are targeted to prepare a patient's bone marrow for transplantation. The primary goal of targeting these molecules is to deplete the host's existing stem cell population (myeloablation) and suppress the immune system (immunosuppression) to facilitate the engraftment of donor or gene-edited cells. Historically, this has been achieved through non-specific genotoxic agents like high-dose chemotherapy and total body irradiation, which carry significant systemic toxicities. Modern therapeutic approaches are shifting toward targeted biologics, specifically focusing on receptors like CD117 (c-Kit) and CD45. CD117 is essential for HSC survival and proliferation; its blockade can selectively clear the stem cell niche without the broad tissue damage associated with traditional conditioning. Similarly, CD45-targeted radioimmunotherapy delivers localized radiation to the hematopoietic system, minimizing off-target effects. These targeted strategies aim to expand the eligibility of HSC transplantation to older patients and those with non-malignant genetic disorders, such as sickle cell disease, by reducing the severe safety concerns associated with conventional conditioning regimens.

Other names

HSC niche conditioning targetsBone marrow conditioning targetsMyeloablative conditioning targetsNon-genotoxic conditioning targetsPre-transplant conditioning targets

Mechanisms include DNA alkylation (chemotherapy), competitive inhibition of growth factor signaling (e.g., c-Kit blockade), antibody-dependent cellular cytotoxicity (ADCC), and targeted radiotherapy to deplete endogenous hematopoietic stem cells and create space in the bone marrow niche.